Ownership and insider activity for Viatris Inc. (VTRS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs).
Price
| Price | $17.60 |
| Market Cap | $20.5B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-30 | Groothuis Leo Frans | A-Award | 2,469 | |
| 2026-09-30 | SIMMONS DAVID S | A-Award | 2,117 | |
| 2026-08-15 | Enrietti Andrew | M-Exempt | 25,134 | |
| 2026-08-15 | Enrietti Andrew | M-Exempt | 999 | |
| 2026-08-15 | Enrietti Andrew | F-InKind | 435 | $7K |
| 2026-08-15 | Enrietti Andrew | F-InKind | 10,931 | $177K |
| 2026-08-15 | Enrietti Andrew | M-Exempt | 25,134 | |
| 2026-08-15 | Enrietti Andrew | M-Exempt | 998 | |
| 2026-06-30 | SIMMONS DAVID S | A-Award | 2,362 | |
| 2026-06-30 | Groothuis Leo Frans | A-Award | 2,756 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $998.8M | $292.1M | $388.1M | $475.6M | $844.4M | $701.2M | $1.26B | $991.9M | $734.8M | $1.35B |
| Short-term Investments | $83.8M | $110.6M | $57.5M | $109.1M | $203.5M | $233.8M | $212.6M | $192.5M | $355.1M | $106.4M |
| Receivables | $3.02B | $3.17B | $2.42B | $3.06B | $4.84B | $4.27B | $4.14B | $4.04B | $3.52B | $3.35B |
| Inventory | $2.46B | $2.54B | $2.58B | $2.67B | $5.47B | $3.98B | $3.52B | $3.47B | $3.85B | $4.00B |
| Total Current Assets | $7.52B | $7.21B | $6.37B | $6.76B | $12.87B | $10.90B | $10.64B | $12.98B | $9.52B | $9.22B |
| Property, Plant & Equipment | $2.32B | $2.34B | $2.17B | $2.40B | $3.78B | $3.48B | $3.28B | $3.01B | $2.92B | $2.89B |
| Goodwill | $9.23B | $10.21B | $9.75B | $9.59B | $12.35B | $12.11B | $10.43B | $9.87B | $9.13B | $6.75B |
| Intangible Assets | $14.45B | $15.25B | $13.66B | $11.65B | $29.68B | $26.13B | $22.61B | $19.18B | $17.07B | $15.10B |
| Total Assets | $34.73B | $35.81B | $32.73B | $31.26B | $61.55B | $54.84B | $50.02B | $47.69B | $41.50B | $37.19B |
| Accounts Payable | $1.35B | $1.45B | $1.24B | $1.06B | $1.35B | $1.06B | $1.16B | $1.38B | $1.36B | $1.29B |
| Short-term Debt | $269.7M | $1.80B | $657.1M | $1.46B | $3.41B | $3.35B | $1.25B | $1.93B | $600,000 | $2.04B |
| Total Current Liabilities | $5.04B | $6.39B | $4.59B | $5.57B | $10.56B | $9.88B | $6.75B | $7.78B | $5.78B | $7.09B |
| Long-term Debt | $15.20B | $12.87B | $13.16B | $11.21B | $22.43B | $19.72B | $18.02B | $16.19B | $14.04B | $12.48B |
| Total Liabilities | $23.61B | $22.50B | $20.57B | $19.37B | $38.60B | $34.35B | $28.95B | $27.22B | $22.87B | $22.48B |
| Retained Earnings | $4.94B | $5.64B | $6.01B | $6.03B | $5.36B | $3.69B | $5.18B | $4.64B | $3.42B | -$388.3M |
| Total Equity | $11.12B | $13.31B | $12.17B | $11.88B | $22.95B | $20.49B | $21.07B | $20.47B | $18.64B | $14.71B |
| Total Debt | $15.47B | $14.66B | $13.82B | $12.92B | $26.16B | $23.36B | $19.53B | $18.37B | $14.31B | $14.70B |
| Net Debt | $14.33B | $14.24B | $13.37B | $12.34B | $25.11B | $22.42B | $18.06B | $17.19B | $13.22B | $13.25B |
| Working Capital | $2.48B | $828.0M | $1.78B | $1.19B | $2.30B | $1.02B | $3.89B | $5.20B | $3.74B | $2.13B |
Financial Health
| Debt / Equity | 0.96 |
| Current Ratio | 1.58 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 0.59 |
Profitability
| Return on Equity | -23.89% |
| Return on Invested Capital | -7.95% |
| Return on Assets | -9.45% |
| Gross Margin | 34.83% |
| Operating Margin | -0.59% |
| Net Margin | -2.79% |
Related companies: BAX · BBIO · ELAN · EXAS · IONS · MRNA · NBIX
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of VTRS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks